Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

NCT05195918 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

COMBINATION_PRODUCT: EGCG 300 mg + Nintedanib
COMBINATION_PRODUCT: EGCG 300 mg + Pirfenidone
COMBINATION_PRODUCT: Placebo 2 capsules + Nintedanib or Pirfenidone
COMBINATION_PRODUCT: EGCG 600 mg + Nintedanib
COMBINATION_PRODUCT: EGCG 600 mg + Pirfenidone
COMBINATION_PRODUCT: Placebo 4 capsules + Nintedanib or Pirfenidone

Sponsor

Hal Chapman

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]